(Q91559544)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

title

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

author name string

Dennis P O'Malley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Yuhang Yang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Saskia Boisot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Sucha Sudarsanam

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Jian-Feng Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Vladislav Chizhevsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Guohua Zhao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Shehla Arain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Lawrence M Weiss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

publication date

13 February 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

page(s)

929-942

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

23 April 2020

copyright license

start time

13 February 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Immunotherapy in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Immune checkpoint modulation for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Complementary versus companion diagnostics: apples and oranges?

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

Mucinous differentiation in colonic adenocarcinoma is associated with a reduction in tumour-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41379-019-0210-3

7 January 2021

10.1038/S41379-019-0210-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30760860%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference